20cm速递｜创业板医药ETF国泰（159377）盘中涨超0.5%，行业政策与创新主线受关注

Core Viewpoint - The article highlights the positive performance of the ChiNext Medical ETF (国泰, 159377) amid supportive policies and a focus on innovation within the pharmaceutical and medical device sectors [1]. Group 1: Industry Policies and Innovations - Recent supportive policies are continuously emerging, leading to a recommendation for innovative drugs and medical devices along with their supply chains [1]. - The high demand for innovative drugs is noted, with a recommendation for Pharma companies that are expected to see a revaluation, as well as Biopharma/Biotech firms whose performance is entering a growth phase [1]. Group 2: Investment Opportunities - The report suggests investment in CXO and upstream pharmaceutical companies that benefit from innovation and a recovery in market conditions [1]. - In the medical device sector, companies that excel in engineering and have successful overseas expansions are recommended for investment [1]. Group 3: Future Catalysts - The report mentions that from 2026 onwards, there will be frequent catalysts in the medical device sector, with a focus on investment opportunities in overseas markets, brain-computer interfaces, and AI in healthcare [1]. Group 4: ETF Performance - The ChiNext Medical ETF (国泰, 159377) tracks the Innovation Medicine Index (创医药指数, 399275), which has a daily price fluctuation limit of 20% and includes listed companies involved in the research, production, and related services of innovative drugs [1].